Class of 2015 AbstractObjectives: Warfarin has historically been the anticoagulant used for the primary prevention of stroke in atrial fibrillation (AF), however three target specific oral anticoagulants, dabigatran, rivaroxaban, and apixaban, have recently been approved for use in this setting. Current literature lacks a comparison of these four drugs in relation to post-stroke outcomes, and this study aims to compare their performance in a natural setting. Methods: This retrospective cohort study identified stroke patients admitted to an academic medical center between January 2013 and December 2014 using the Quintiles, Inc.-American Heart Association Get With The Guidelines-Stroke database; pertinent data was collected from the database ...
Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy ...
C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...
Aims Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (S...
Objective: To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC)...
No studies have directly compared the effectiveness and safety of direct oral anticoagulants (DOACs)...
In this overview we address the three phase III studies that compared new oral anticoagulants (dabig...
ObjectiveTo compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) d...
Introduction: New oral anticoagulants are non-inferior compared with warfarin regarding stroke preve...
Background and Purpose-This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observationa...
Importance: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagula...
Objective To examine the association between warfarin treatment and longitudinal outcomes after isch...
Aim: To investigate the differences in the characteristics and clinical outcomes of recently diagnos...
Atrial fibrillation (AF) is an important cause of ischemic stroke and is the underlying cause of \u3...
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved for stroke pr...
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all ...
Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy ...
C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...
Aims Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (S...
Objective: To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC)...
No studies have directly compared the effectiveness and safety of direct oral anticoagulants (DOACs)...
In this overview we address the three phase III studies that compared new oral anticoagulants (dabig...
ObjectiveTo compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) d...
Introduction: New oral anticoagulants are non-inferior compared with warfarin regarding stroke preve...
Background and Purpose-This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observationa...
Importance: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagula...
Objective To examine the association between warfarin treatment and longitudinal outcomes after isch...
Aim: To investigate the differences in the characteristics and clinical outcomes of recently diagnos...
Atrial fibrillation (AF) is an important cause of ischemic stroke and is the underlying cause of \u3...
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved for stroke pr...
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all ...
Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy ...
C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...
Aims Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (S...